About Us: Leadership

Steve Carchedi

CEO
Allarity Leadership Steve Carchedi

Steve has served as CEO and a Director of Allarity Therapeutics since September 2019. He brings more than 30 years of commercial industry experience focused in oncology from several leading multinational pharmaceutical biotech companies. Steve has served in CEO positions in both privately owned and Nasdaq-listed biotech companies, all with a late stage oncology focus in which he has led financing, commercialization, and re-structuring activities.

He was previously President & Chief Executive Officer of Apexian Pharmaceuticals, an early stage oncology discovery and development company focused in novel targets to treat cancer, and earlier served as Chief Executive Officer of Raphael Pharmaceuticals (formerly Cornerstone Pharmaceuticals), an oncology company focused in cancer metabolism.

Earlier in his career, Steve served as the Senior Vice President and President, Commercial Operations (North America) for Mallinckrodt Pharmaceuticals leading the company listing on NYSE. In addition, he previously held senior leadership positions at General Electric, Johnson & Johnson, Eli Lilly & Company, and Bristol Myers Squibb. In addition to his executive experience, Steve currently serves on the Board of Directors of Sunesis Pharmaceuticals and Bionumerik Pharmaceuticals. He previously served on the Board of Directors for Apexian Pharmaceuticals, Cornerstone Pharmaceuticals, and PCAsso Diagnostics, LLC, and was co-chair of the BioNJ Personalized Medicine & Diagnostics Committee Council (CMOC), the Ontario Institute of Cancer Research Commercial Committee (OICR) and the Pharmaceutical Industry Board of the American Pediatric Family Foundation.

Steve received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University. 

Number of warrants: 3 523 875.

Henrik Moltke

Chief Financial Officer
Allarity Leadership Henrik Moltke

Henrik brings more than 30 years of experience in CFO and Senior Vice President roles within the life sciences and health care sectors, and joined our executive team in 2019. The primary focus in his career has been in venture financing, including IPOs as well as follow on capital increases in the public markets, investor relations, finance, project management, and strategic development. 

Henrik has formerly served in such senior roles with companies like Scandinavian Micro Biodevices ApS, Astion Pharma A/S, NeuroSearch A/S, Novo A/S, and Ferrosan A/S.  He has also a broad financial and managerial experience from several listed and unlisted companies as member of their Boards of Directors. 

Henrik holds a Masters Degree in international economics and strategic management from Copenhagen Business School, Denmark. Henrik is a member of the Board of Directors of Initiator Pharma A/S and Hartmanns A/S.

Number of warrants: 2 114 324.

 

Steen Knudsen

Chief Scientific Officer
Allarity Leadership Steen Knudsen

Steen is a co-founder of Oncology Venture A/S (now Allarity Therapeutics) and the inventor of DRP®, the Drug Response Prediction Platform which is Allarity’s core technology and science platform. Knudsen is a Professor of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. He co-founded the company in 2004.

Number of shares: 6 248 847. 

Marie Foegh

Chief Medical Officer
Allarity Leadership Marie Foegh

Marie brings thirty years of experience in the pharmaceutical and biotechnology industries to our senior management team and has a strong track record leading successful clinical development of therapeutics, including regulatory and medical affairs. She joined the company in 2017.

She leads clinical development of our current precision medicine oncology pipeline, including our lead assets stenoparib, dovitinib, and Ixempra®.

She previously led the successful development and regulatory approval of more than 10 novel drug products in the U.S. and U.K., within oncology, endocrinology and cardiology. Marie has fluency in regulatory interactions with the FDA and EMEA, including INDs, NDAs, IDEs (for predictive biomarkers and/or companion diagnostics), and product issues.

She also manages interactions with the oncology key opinion leaders that sit on our Scientific Advisory Board.

She holds both Medical Doctorate (M.D.) and Doctorate of Science (Dr.Sc.) degrees, and is a member of the American College of Physicians (ACP), American Medical Association (AMA), the American Society of Clinical Oncology, and the American College of Obstetricians  and Gynecologists (ACOG).

Number of shares:  187 807.

James G. Cullem

Senior Vice President, Corporate Development
Allarity Leadership James Cullem

James is an experienced biotechnology executive and has been part of our senior team since 2014. He brings 20+ years of diverse experience in life sciences organizational management, business development & licensing, intellectual property & technology transfer/commercialization, partnership creation/management, and strategic planning as a member of executive teams.

During his tenure with Allarity, James has been responsible for the identification and acquisition of most of our lead clinical oncology assets, including big pharma therapeutics dovitinib (from Novartis) and stenoparib (from Eisai). He leads the company’s business development discussions as well as  clinical program out-licensing and partnership negotiations, both in the U.S. and worldwide.

James has previously designed and negotiated a broad span of life science deals, has founded and led several early-stage biotech companies, and is a catalyst for businesses taking the next step in the fields of precision medicine and predictive/companion diagnostics, novel drug targets, proteomics and genomics, and clinical-stage cancer therapeutic development.

He holds a B.S. degree in Biochemistry, a JD degree specializing in patent & I.P. law, and has registered patent attorney status.

Thomas Jensen

SVP, Information Technology
Founder
Allarity Leadership Thomas Jensen

Thomas Jensen is pioneering the bridging of good science, effective laboratory techniques, and bioinformatics to advance the understanding of the biology of cancer. He founded and leads Allarity’s laboratories in Denmark and in the USA. Alongside nurturing our global laboratories, he is instrumental in building our investor relations operations, securing operational financing, and fostering the business growth of Allarity Therapeutics.

Amongst Thomas’ accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing. This allows for high resolution analysis of cancer patients’ biopsies. His inventions are an important foundation of the DRP® -Drug Response Prediction platform. Thomas Jensen co-founded Allarity Therapeutics A/S in 2004.

Number of shares:  713 620.

Number of warrants: 920 520.

Oncology Venture is now

Allarity Therapeutics

At Allarity Therapeutics, we are defining a bright future for patients in a new paradigm of precision cancer treatments. Our mission is to bring clarity to personalized oncology medicines, marrying innovative therapies and superior companion diagnostics, to help fully realize the promise of personalized cancer care.

Allarity Therapeutics Logo